Efficacy and safety of ranibizumab monotherapy versus ranibizumab in combination with verteporfin photodynamic therapy in patients with polypoidal choroidal vasculopathy: 12-month outcomes in the Japanese cohort of EVEREST II study

Kanji Takahashi1 Department of Ophthalmology, Kansai Medical University, Osaka, Japan, [email protected]Correspondence[email protected]

Masahito Ohji2 Department of Ophthalmology, Shiga University of Medical Science, Otsu, Japan

Hiroko Terasaki3 Department of Ophthalmology, Nagoya University Graduate School of Medicine, Nagoya, Japan

Shigeru Honda4 Division of Ophthalmology, Department of Surgery, Kobe University Graduate School of Medicine, Kobe, Japan

Philippe Margaron5 Department of Ophthalmology, Novartis Pharma AG, Basel, Switzerland

Tadhg Guerin6 Department of Ophthalmology, Novartis Ireland Limited, Dublin, Ireland

Mitsuko Yuzawa7 Division of Ophthalmology, Department of Visual Sciences, Nihon University School of Medicine, Tokyo, Japan

Your download is now in progress and you may close this window